Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Non-Current Debt (2016 - 2022)

Aptevo Therapeutics' Non-Current Debt history spans 7 years, with the latest figure at $1.5 million for Q4 2022.

  • For Q4 2022, Non-Current Debt fell 60.72% year-over-year to $1.5 million; the TTM value through Dec 2022 reached $1.5 million, down 60.72%, while the annual FY2022 figure was $1.5 million, 60.72% down from the prior year.
  • Non-Current Debt for Q4 2022 was $1.5 million at Aptevo Therapeutics, down from $1.9 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $25.2 million in Q3 2020 and bottomed at $1.5 million in Q4 2022.
  • The 5-year median for Non-Current Debt is $9.3 million (2018), against an average of $11.1 million.
  • The largest annual shift saw Non-Current Debt skyrocketed 38.93% in 2019 before it plummeted 84.08% in 2021.
  • A 5-year view of Non-Current Debt shows it stood at $19.3 million in 2018, then rose by 1.45% to $19.6 million in 2019, then grew by 2.54% to $20.1 million in 2020, then plummeted by 81.51% to $3.7 million in 2021, then crashed by 60.72% to $1.5 million in 2022.
  • Per Business Quant, the three most recent readings for APVO's Non-Current Debt are $1.5 million (Q4 2022), $1.9 million (Q3 2022), and $2.4 million (Q2 2022).